Association between a novel inflammation-lipid composite marker CRP/HDL and erectile dysfunction: evidence from a large national cross-sectional study
Open Access
- 20 November 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1492836
Abstract
Background: Erectile dysfunction (ED) is one of the most common male sexual disorders, closely associated with both inflammation and lipid dysregulation. Recently, a novel inflammation-lipid composite marker, CRP/HDL, has been proposed to integrate the impact of both pathways on health, yet its relationship with ED remains unexplored. Therefore, our study aimed to investigate the potential association between the CRP/HDL ratio and ED.Methods: We utilized data from the NHANES database, known for its comprehensive and high-quality information. A total of 3,633 eligible participants from the 2001-2004 cycles were included. ED was assessed using a single-item questionnaire, while CRP and HDL were measured from blood samples. Multivariable regression analyses were performed to evaluate the association between CRP/HDL and ED after adjusting for potential confounders. Additionally, subgroup and sensitivity analyses were conducted to test the robustness of the results, and the linear trend between CRP/HDL and ED was visualized through smooth curve fitting.Results: Among the 3,633 participants, 1,027 had a history of ED. The CRP/HDL ratio was significantly higher in participants with ED compared to those without (10.53 ± 0.69 vs. 7.43 ± 0.35, P<0.001). In the regression analysis, a higher continuous CRP/HDL ratio was significantly associated with increased ED risk even after full adjustment (OR: 1.17, 95% CI: 1.05, 1.30; P = 0.01). Compared to Q1 of the CRP/HDL ratio, participants in Q2, Q3, and Q4 had progressively higher ED risks: Q2 (OR: 1.40, 95% CI: 1.01, 1.95; P = 0.05), Q3 (OR: 1.58, 95% CI: 1.10, 2.27; P = 0.02), and Q4 (OR: 1.85, 95% CI: 1.31, 2.60; P = 0.005), showing a clear linear trend. Subgroup analyses indicated consistent results across various populations with no significant interactions, and sensitivity analysis revealed that the CRP/HDL ratio also increased the risk of severe ED (OR: 1.14, 95% CI: 1.03, 1.26; P = 0.02).Conclusion: This is the first study to establish a significant positive association between an elevated CRP/HDL ratio and ED risk, suggesting its potential role in screening for ED risk and guiding timely interventions. However, further large-scale studies are needed to confirm our findings and explore the underlying mechanisms.Keywords
This publication has 52 references indexed in Scilit:
- Association of METS-IR index with prevalence of erectile dysfunction in US adults: a cross-sectional studyInternational Urology and Nephrology, 2024
- Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk PopulationsJAMA Cardiology, 2022
- High Density Lipoprotein Cholesterol / C Reactive Protein Ratio in Heart Failure with Preserved Ejection FractionESC Heart Failure, 2021
- Evaluation of Arterial Erectile Dysfunction Using Shear Wave ElastographyJournal of Ultrasound in Medicine, 2020
- From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndromeJournal of Endocrinological Investigation, 2018
- Impact of Combined C-Reactive Protein and High-Density Lipoprotein Cholesterol Levels on Long-Term Outcomes in Patients With Coronary Artery Disease After a First Percutaneous Coronary InterventionThe American Journal of Cardiology, 2015
- Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable anginaClinica Chimica Acta, 2012
- Inflammation, Metabolic Syndrome, Erectile Dysfunction, and Coronary Artery Disease: Common LinksEuropean Urology, 2007
- Circulating markers of endothelial function in cardiovascular diseaseClinica Chimica Acta, 2006
- Erectile dysfunction and atherosclerosisCurrent Atherosclerosis Reports, 2002